XWEL vs. MRM, PSTV, HEPA, AQB, ASLN, VVOS, CANF, TRVN, VCNX, and LFLY
Should you be buying XWELL stock or one of its competitors? The main competitors of XWELL include MEDIROM Healthcare Technologies (MRM), Plus Therapeutics (PSTV), Hepion Pharmaceuticals (HEPA), AquaBounty Technologies (AQB), ASLAN Pharmaceuticals (ASLN), Vivos Therapeutics (VVOS), Can-Fite BioPharma (CANF), Trevena (TRVN), Vaccinex (VCNX), and Leafly (LFLY). These companies are all part of the "medical" sector.
MEDIROM Healthcare Technologies (NYSE:MRM) and XWELL (NASDAQ:XWEL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations.
8.7% of XWELL shares are held by institutional investors. 40.2% of MEDIROM Healthcare Technologies shares are held by company insiders. Comparatively, 4.9% of XWELL shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, XWELL had 1 more articles in the media than MEDIROM Healthcare Technologies. MarketBeat recorded 2 mentions for XWELL and 1 mentions for MEDIROM Healthcare Technologies. XWELL's average media sentiment score of 0.00 equaled MEDIROM Healthcare Technologies'average media sentiment score.
XWELL received 3 more outperform votes than MEDIROM Healthcare Technologies when rated by MarketBeat users.
XWELL has a consensus price target of $7.00, suggesting a potential upside of 266.49%. Given MEDIROM Healthcare Technologies' higher possible upside, analysts plainly believe XWELL is more favorable than MEDIROM Healthcare Technologies.
MEDIROM Healthcare Technologies has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, XWELL has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500.
MEDIROM Healthcare Technologies has higher revenue and earnings than XWELL.
MEDIROM Healthcare Technologies has a net margin of 0.00% compared to MEDIROM Healthcare Technologies' net margin of -92.14%. XWELL's return on equity of 0.00% beat MEDIROM Healthcare Technologies' return on equity.
Summary
MEDIROM Healthcare Technologies beats XWELL on 7 of the 13 factors compared between the two stocks.
Get XWELL News Delivered to You Automatically
Sign up to receive the latest news and ratings for XWEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XWEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
